Rusfertide  (Synonyms: PTG-300)

Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis^[1][2].

Rusfertide limits the iron toxicity in red blood cells (RBCs) (1 mg/kg, s.c., once every two days, for 49 days) and transferrin-saturation (2.5 mg/kg, s.c., once every two days, for 2 weeks), improves oxygen carrying capacity of RBCs, attenuates the anemia and iron deposition in mice models for β-thalassemia and hereditary hemochromatosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2441.95

C₁₁₄H₁₈₁N₂₇O₂₈S₂

1628323-80-7

{Asp(N-(3-methyl-1-oxobutyl))}-Thr-His-Phe-Pro-Cys-Ile-{Lys(γGlu-C16 acid)}-Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys-Lys-NH2 (disulfide bridge: Cys6-Cys16)

{Asp(N-(3-methyl-1-oxobutyl))}-THFPCI-{Lys(γGlu-C16 acid)}-FEPRSKGCK-NH2 (disulfide bridge: Cys6-Cys16)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Taranath R, et al., Regulation of iron homeostasis by PTG-300 improves disease parameters in mouse models for beta-thalassemia and hereditary hemochromatosis[J]. Blood, 2019, 134: 3540.

  [2]. Kremyanskaya M, et al., PTG-300 eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera patients[J]. Blood, 2020, 136: 33-35.